MARS生物成像公司筹集了1 500万美元,以利用CERN技术扩大其便携式高射线X光扫描仪。 MARS Bioimaging raised $15M to expand its portable, high-res color X-ray scanners using CERN tech.

新西兰医疗设备公司MARS生物成像公司A系列筹集了1 500万美元的资金,以扩大其便携式光子光子计CT扫描仪、MARSExtremiclab系统,这些系统提供高分辨率的3D色X射线成像,没有对比剂。 MARS Bioimaging, a New Zealand medical device company, has raised $15 million in Series A funding to expand its portable spectral photon-counting CT scanners, the MARS Extremity and Microlab systems, which offer high-resolution 3D color X-ray imaging without contrast agents. 该技术以欧洲核核研究组织开发的Medipix3芯片为基础,能够对软组织、骨骼和植入物进行详细的可视化。 The technology, based on CERN-developed Medipix3 chipsets, enables detailed visualization of soft tissue, bone, and implants. 基金将支持新西兰、美国以及印度等新兴市场的增长,扩大销售和研究团队。 Funds will support growth in New Zealand, the U.S., and emerging markets like India, with expanded sales and research teams. 该回合由太平洋频道领导,新加坡和瑞士的投资者通过新西兰的积极投资者加方案提供支持。 The round was led by Pacific Channel, with backing from investors in Singapore and Switzerland via New Zealand’s Active Investor Plus programme.